Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04938141 · ClinicalTrials.gov registry record
MEOI and HRQoL in CLL Patients Treated With BTKis
A clinical trial of Chronic Lymphocytic Leukemia, sponsored by AstraZeneca.
- Completed
- Registry status
- 23
- Enrollment target
- 16
- Study locations
NCT04938141: Completed study of Chronic Lymphocytic Leukemia, sponsored by AstraZeneca.
NCT04938141 is a study of Chronic Lymphocytic Leukemia that has completed, run by AstraZeneca. The registered enrollment target is 23 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04938141, a study of Chronic Lymphocytic Leukemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
Primary Outcome
To describe the demographic and clinical characteristics of CLL patients who have recently initiated acalabrutinib or ibrutinib.
Conditions Studied
Study Locations (16)
Florida
- Research Site - Boca Raton
- Research Site - Fort Lauderdale
- Research Site - St. Petersburg
- Research Site - Tallahassee
- Research Site - Tamarac
- Research Site - Tampa
California
- Research Site - Fountain Valley
- Research Site - Redlands
Pennsylvania
- Research Site - Philadelphia
- Research Site - York
Georgia
- Research Site - Savannah
Hawaii
- Research Site - Honolulu
Mississippi
- Research Site - Jackson
New Jersey
- Research Site - Berkeley Heights
New York
- Research Site - Amherst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2024-09-26 |
What the finished NCT04938141 record still lists
NCT04938141 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT04938141 lists 16 locations in 9 states (Florida, California, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT04938141 about?
NCT04938141 is a clinical study titled "MEOI and HRQoL in CLL Patients Treated With BTKis". This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
What is the current status of trial NCT04938141?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2021-10-07. Estimated completion is 2024-09-26.
What conditions does trial NCT04938141 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
Who is sponsoring clinical trial NCT04938141?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04938141 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Hawaii, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04938141's enrollment target sits among peer trials
23 155th of 187 higher than 29 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI